Drugs / 111In-IPN01087
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04632199 | Mar → Dec 2021 | colorectal cancer, pancreatic ductal adenocarcinoma | Ipsen | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 111In-IPN01087 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04632199 ↗ |
| Known as | 111Indium-labelled IPN01087 | “111Indium-labelled IPN01087 (111In-IPN01087) is developed as a radioactive diagnostic imaging agent in patients with colorectal or pancreatic cancer.” NCT04632199 ↗ |
| Modality | Diagnostic / imaging agent | “radioactive diagnostic imaging agent” NCT04632199 ↗ |
| Route | Intravenous | “single intravenous injection” NCT04632199 ↗ |